Results 121 to 130 of about 182,500 (270)
IgE-mediated anaphylaxis induced by pembrolizumab
International audienceThe increasing use of biologics in cancer treatment is associated with an increase in drug-related hypersensitivity reactions (HSR) of varying severity.
Perotin, Jeanne-Marie +3 more
core +1 more source
ABSTRACT Background Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. Methods A 55‐year‐old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5.
Joaquin Austerlitz +7 more
wiley +1 more source
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer +3 more
wiley +1 more source
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks +4 more
doaj +1 more source
Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy [PDF]
A 53-year-old post-menopausal Indian female presented with invasive ductal carcinoma, treated with neoadjuvant chemotherapy and pembrolizumab due to a PD-L1 combined positive score of 5.
Sohail Singh Sodhi +4 more
core +1 more source
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris +4 more
wiley +1 more source
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD +14 more
doaj +1 more source
Immune-related adverse events after commencing pembrolizumab therapy.
Immune-related adverse events after commencing pembrolizumab therapy.
Hiroyuki Kurebe (5693162) +13 more
core +1 more source
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia +4 more
wiley +1 more source
Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor ...
Primo N. Lara +19 more
doaj +1 more source

